Treating Hemophilia A – How High Should the Factor Level Be and How Can the Newest Addition of Therapy Support It
Released On
February 27, 2024
Expires On
February 27, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology, Hospitalist, Pediatrics, Pharmacy, and Primary Care
Topic(s)
Hemophilia, Pediatrics
This activity is jointly provided by P2P Syncro and Postgraduate Institute for Medicine.
This activity is supported by an independent educational grant from Sanofi.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour
- Physician Assistants — 1.0 CE Credit
- Pharmacists — 1.0 Contact Hour
Target Audience
Hematologists, pediatricians, internists, family medicine physicians, hospitalists, surgeons, pharmacists, and advanced practitioners who manage patients with hemophilia.
Program Overview
Treatment goals in hemophilia evolved and evidence on targeting higher factor VIII activity levels in treatment is growing. This CME course will discuss how a novel factor replacement therapy supports achieving the higher factor level. Clinical scenarios on how to treat young athletic patients or adults on antiplatelet or anticoagulation therapies are included. Experience of using efanesoctocog alfa for peri-operative management will be discussed.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess evidence on targeting a higher factor level for near-zero joint bleed.
- Discuss factor VIII activity levels achieved with current hemophilia therapies.
- Evaluate data on a novel therapy that achieves higher factor level at reduced treatment burden.
Faculty
Barbara A. Konkle, MD
Dr. Konkle is a professor at the University of Washington, WA, and research Director of Washington Center for Bleeding Disorders. Dr. Konkle is a nationally recognized expert in the field of hemophilia. She serves on the Board of Directors for the World Federation of Hemophilia and the Foundation for Women and Girls with Blood Disorders.
Lynn Malec, MD
Dr. Malec is an associate professor at the Medical College of Wisconsin, WI, and medical director of Comprehensive Center for Bleeding Disorders, Versiti Blood Research Institute. Dr. Malec has published on the topic of factor levels and outcome in hemophilia. She’s the lead investigator of a clinical trial on the use of a novel therapy in pediatric hemophilia patients.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and P2P Syncro. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-24-040-H01-P. Type of Activity: Knowledge
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until February 22, 2025. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
- Barbara A Konkle, MD
- Consulting: BeBiopharma, BioMarin, Novo Nordisk, Pfizer, Regeneron, Veralox
- Research support: CSL Behring/Uniqure, Genentech, Pfizer, Sanofi/Bioverativ, Takeda
- Speaker Bureau: BioMaring, Pfizer
- Lynn Malec, MD
- Consulting: CSL Behring, Novo Nordisk, Sanofi, Sobi, Spark Therapeutics, Takeda
- Research support: Sanofi
- Speaker Bureau: CSL, Sanofi
The PIM planners and others have nothing to disclose. The P2P Syncro planners and others have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Postgraduate Institute for Medicine (PIM) requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].